Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumab

BackgroundLoss of skeletal muscle mass may serve as a valuable indicator of treatment efficacy and survival in individuals with lung cancer undergoing immunotherapy. This investigation sought to pinpoint accessible markers that could reflect the presence of muscle degradation.MethodsA retrospective...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Serena Eccher, Marco Sposito, Ilaria Trestini, Ilaria Mariangela Scaglione, Luca Pasqualin, Daniela Tregnago, Alice Avancini, Jessica Insolda, Linda Confortini, Alessandra Dodi, Alessio Stefani, Marco Cintoni, Isabella Sperduti, Maria Cristina Mele, Fotios Loupakis, Marcello Tiseo, Emilio Bria, Michele Milella, Sara Pilotto, Lorenzo Belluomini
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2025-08-01
Serie:	Frontiers in Oncology
Soggetti:	non-small cell lung cancer (NSCLC) muscle wasting immune checkpoint inhibitors (ICIs) thyroid hormones sarcopenia body composition
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1635321/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!